In the News

Nurofen fined heavily for mis-leading consumers

Graham Watson

16th December 2016

Another instance of the regulator intervening to protect consumers from exploitation by another pharmaceutical company. In this instance, the manufacturer of Nurofen, Reckitt Benckiser, has seen its fine increase from $1.7m to $6m, for misleading branding of identical products.

My take on this? Don't buy Nurofen in the first place - generic ibuprofen is identical. However, that said, some studies suggest that pricier painkillers are 'better' at providing pain relief - if only because of their psychosomatic effects.

Graham Watson

Graham Watson has taught Economics for over twenty years. He contributes to Tutor2U, reads voraciously and is interested in all aspects of Teaching and Learning.

© 2002-2022 Tutor2u Limited. Company Reg no: 04489574. VAT reg no 816865400.